Akrevia Therapeutics, a privately-held biopharmaceutical company focused on developing highly-potent, tumour-targeted immuno-oncology therapeutics, announced yesterday that it has named Joseph Farmer as its new Chief Operating Officer.
Farmer will lead Akrevia's business development, finance, administrative, and business operations functions. He will report to Rene Russo, PharmD, Akrevia's Chief Executive Officer.
Farmer is a biopharma executive with more than 20 years of industry experience. Prior to joining Akrevia, he most recently served as Senior Vice President, General Counsel, and Corporate Secretary at Tesaro, Inc. Prior to Tesaro, he was Chief Corporate Counsel and Assistant Secretary at Cubist Pharmaceuticals Inc.
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories